On Friday, however, Novo Nordisk announced top-line results in yet another trial. While the results don't initially sound as ...

Health-care companies rose as traders rotated back into the sector amid optimism about blockbuster drugs. Novo Nordisk shares rose by more than 8% for one of their biggest gains in recent years after ...

Amycretin could give Novo a buzzy product in an newly competitive obesity market. It works similarly to existing GLP-1 ...

Novo Nordisk (NVO) was slammed by a U.K. trade group for violating voluntary codes and discrediting the pharmaceutical industry over a failure ...

Here are some of the major companies whose stocks moved on the week’s news.

Novo Nordisk shares were 9.5% higher after the pharmaceutical giant said an experimental weight-loss shot showed patients ...

Novo Nordisk shares jump close to 14% on promising trial results for amycretin, a once-weekly obesity drug, signaling fierce ...

The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger ...

Novo Nordisk (NVO) stock jumped 12% in pre-market trading Friday after it released promising results of an early-stage weight ...

Along with AZ, BrightInsight is working on digital health projects with CSL Behring in the area of rare and serious diseases, with Novo Nordisk in the diabetes area, and with Roche for a dosing ...

Researchers in the US have developed an artificial intelligence algorithm that can sift through electronic health records (EHRs) and help physicians to detect undiagnosed cases of long COVID.

Sino Biopharmaceutical CEO Eric Tse discusses the outlook of the company, Asian pharmaceutical markets, and the potential impacts from US President Donald Trump's tariffs and policy. Tse speaks to ...